MA56022A - Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3 - Google Patents

Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3

Info

Publication number: MA56022A
Authority: MA; Morocco
Prior art keywords: inhibitors; quinazoline derivatives; amino quinazoline; amino; derivatives
Prior art date: 2019-05-31

Application number

MA056022A

Other languages

English (en)

Inventor

Charles Baker-Glenn

Matteo Biagetti

Paolo Bruno

Claudio Fiorelli

Sara Guariento

Kim Louise Hirst

Daniele Pala

Daniela Pizzirani

Paolo Ronchi

De Poël Hervè Van

Original Assignee

Chiesi Farm Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-05-31

Filing date

2020-05-28

Publication date

2022-04-06

2020-05-28 Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa

2022-04-06 Publication of MA56022A publication Critical patent/MA56022A/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Pulmonology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)

MA056022A 2019-05-31 2020-05-28 Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3 MA56022A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP19177604		2019-05-31
EP19201168		2019-10-02

Publications (1)

Publication Number	Publication Date
MA56022A true MA56022A (fr)	2022-04-06

Family

ID=70861506

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA056021A MA56021A (fr)	2019-05-31	2020-05-28	Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3
MA056022A MA56022A (fr)	2019-05-31	2020-05-28	Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
MA056021A MA56021A (fr)	2019-05-31	2020-05-28	Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3

Country Status (20)

Country	Link
US (2)	US12466820B2 (fr)
EP (2)	EP3976180A1 (fr)
JP (3)	JP7641917B2 (fr)
KR (2)	KR20220016498A (fr)
CN (3)	CN114269432B (fr)
AU (2)	AU2020285336A1 (fr)
BR (2)	BR112021021738A2 (fr)
CA (2)	CA3139018A1 (fr)
CL (1)	CL2021003165A1 (fr)
CO (1)	CO2021017031A2 (fr)
GE (2)	GEP20257823B (fr)
IL (1)	IL288405A (fr)
MA (2)	MA56021A (fr)
MX (2)	MX2021014115A (fr)
PE (1)	PE20220934A1 (fr)
PH (1)	PH12021552881A1 (fr)
SA (1)	SA521430920B1 (fr)
SG (1)	SG11202112187YA (fr)
WO (2)	WO2020239951A1 (fr)
ZA (1)	ZA202108273B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MA56038B1 (fr)	2019-05-31	2024-11-29	Janssen Pharmaceutica Nv	Inhibiteurs à petite molécule de kinase induisant nf-kb
MX2021014441A (es)	2019-05-31	2022-01-06	Ikena Oncology Inc	Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
GEP20257823B (en) *	2019-05-31	2025-11-10	Chiesi Farm Spa	Amino quinazoline derivatives as p2x3 inhibitors
WO2020239953A1 (fr) *	2019-05-31	2020-12-03	Chiesi Farmaceutici S.P.A.	Dérivés de pyridopyrimidines utilisés en tant qu'inhibiteurs de p2x3
WO2022063205A1 (fr) *	2020-09-24	2022-03-31	中国医药研究开发中心有限公司	Composé aryl formamide, son procédé de préparation et ses utilisations médicales
EP4234548A4 (fr) *	2020-10-20	2024-10-23	Suzhou Zelgen Biopharmaceutical Co., Ltd.	Inhibiteur d'amine benzo ou pyridopyrimidine substitué, son procédé de préparation et son application
AU2021386684A1 (en) *	2020-11-27	2023-05-25	Chiesi Farmaceutici S.P.A.	(aza)quinoline 4-amines derivatives as p2x3 inhibitors
CN116601149A (zh) *	2020-11-27	2023-08-15	奇斯药制品公司	作为p2x3抑制剂的氨基喹唑啉衍生物
CN112661803A (zh) *	2020-12-17	2021-04-16	上海药明康德新药开发有限公司	DNA编码化合物库构建中On-DNA 4-胺基喹唑啉化合物的合成方法
MX2023007550A (es) *	2020-12-22	2023-11-14	Mekanistic Therapeutics Llc	Compuestos de aminobencil heteroarilo sustituidos como inhibidores de receptor de factor de crecimiento epidermico (egfr) y/o fosfoinositol 3-cinasa (pi3k).
WO2022171118A1 (fr) *	2021-02-10	2022-08-18	石药集团中奇制药技术（石家庄）有限公司	Composé ayant une activité antitumorale et son utilisation
CN115677601B (zh) *	2021-07-29	2025-06-03	石药集团中奇制药技术（石家庄）有限公司	一种具有抗肿瘤活性的化合物及其用途
WO2024235225A1 (fr) *	2023-05-15	2024-11-21	苏州泽璟生物制药股份有限公司	Inhibiteur de cycle fusionné à la pyrimidine substitué, son procédé de préparation et son utilisation
AR132741A1 (es)	2023-05-22	2025-07-23	Chiesi Farm Spa	Sales de derivados de aminoquinazolina
WO2024240728A1 (fr)	2023-05-22	2024-11-28	Chiesi Farmaceutici S.P.A.	Procédé et intermédiaires pour la préparation d'un inhibiteur de p2x3
WO2025101598A1 (fr) *	2023-11-07	2025-05-15	Zeno Management, Inc.	Composés pyrimidiques bicycliques, procédés et utilisations associés

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PH31122A (en) *	1993-03-31	1998-02-23	Eisai Co Ltd	Nitrogen-containing fused-heterocycle compounds.
JP4342007B2 (ja)	1998-08-10	2009-10-14	大日本住友製薬株式会社	キナゾリン誘導体
ES2391636T3 (es) *	2004-03-05	2012-11-28	F. Hoffmann-La Roche Ag	Diaminopirimidinas como antagonistas de P2X3 y P2X2/3
WO2007020194A1 (fr) *	2005-08-15	2007-02-22	F. Hoffmann-La Roche Ag	Derives de piperidine et de piperazine en tant qu'antagonistes de p2x3
EP1924264B9 (fr)	2005-09-01	2014-02-19	F.Hoffmann-La Roche Ag	Diaminopyrimidines comme modulateurs p2x3 et p2x2/3
EP2592070B1 (fr)	2006-06-29	2016-08-31	F. Hoffmann-La Roche AG	Arylamides de tétrazole substitués
CA2682162C (fr)	2007-04-02	2016-05-10	Renovis, Inc.	Composes heterocycliques fusionnes avec pyrid-2-yl, et leurs compositions et utilisations
HRP20130867T1 (hr)	2007-04-17	2013-10-25	Evotec Ag	Kondenzirani heterocikliäśki spojevi 2-cijanofenila, te njihovi pripravci i uporaba
US8946439B2 (en)	2008-02-29	2015-02-03	Evotec Ag	Amide compounds, compositions and uses thereof
US20110237578A1 (en)	2008-09-18	2011-09-29	Zhi-Liang Wei	Amide compounds, compositions and uses thereof
WO2012064973A2 (fr)	2010-11-10	2012-05-18	Infinity Pharmaceuticals, Inc.	Composés hétérocycliques et utilisations de ceux-ci
CN104903300B (zh) *	2012-12-27	2018-04-17	霍夫曼-拉罗奇有限公司	Comt抑制剂
TWI637949B (zh)	2013-06-14	2018-10-11	塩野義製藥股份有限公司	胺基三衍生物及含有其等之醫藥組合物
EP3200797A1 (fr) *	2014-09-30	2017-08-09	Bristol-Myers Squibb Company	Inhibiteurs de kinases à base de quinazoline
JPWO2016084922A1 (ja)	2014-11-28	2017-09-07	塩野義製薬株式会社	１，２，４−トリアジン誘導体およびその医薬組成物
WO2016088838A1 (fr)	2014-12-04	2016-06-09	塩野義製薬株式会社	Dérivé de purine et composition pharmaceutique le contenant
JP6544665B2 (ja)	2014-12-09	2019-07-17	バイエルアクチェンゲゼルシャフトＢａｙｅｒＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	１，３−チアゾール−２−イル置換ベンズアミド
WO2017011729A1 (fr)	2015-07-16	2017-01-19	Patara Pharma, LLC	Polythérapies pour le traitement de maladies pulmonaires
EP3355889B1 (fr)	2015-09-29	2023-02-15	Afferent Pharmaceuticals Inc.	Modulateurs des récepteurs p2x3 et p2x2/3 de diaminopyrimidine destinés à être utilisés dans le traitement de la toux
ES2918589T3 (es) *	2015-11-25	2022-07-19	Convergene Llc	Inhibidores de bromodomios BET bicíclicos y usos de los mismos
EP3478674B1 (fr) *	2016-06-30	2020-05-13	Gilead Sciences, Inc.	4,6-diaminoquinazolines utilisées comme modulateurs de cot et leurs méthodes d'utilisation
WO2018035061A1 (fr)	2016-08-15	2018-02-22	Neupharma, Inc.	Entités chimiques, compositions et méthodes particulières
EP3878850A1 (fr) *	2016-12-22	2021-09-15	Boehringer Ingelheim International GmbH	Nouvelles quinazolines substituées benzylamino et dérivés en tant qu'inhibiteurs de sos1
GB201700814D0 (en)	2017-01-17	2017-03-01	Liverpool School Tropical Medicine	Compounds
TWI762634B (zh) *	2017-05-05	2022-05-01	大陸商上海赫普化醫藥技術有限公司	胺基-芳基-苯甲醯胺化合物及其使用方法
WO2020239953A1 (fr)	2019-05-31	2020-12-03	Chiesi Farmaceutici S.P.A.	Dérivés de pyridopyrimidines utilisés en tant qu'inhibiteurs de p2x3
GEP20257823B (en)	2019-05-31	2025-11-10	Chiesi Farm Spa	Amino quinazoline derivatives as p2x3 inhibitors

2020
- 2020-05-28 GE GEAP202015818A patent/GEP20257823B/en unknown
- 2020-05-28 CA CA3139018A patent/CA3139018A1/fr active Pending
- 2020-05-28 KR KR1020217043072A patent/KR20220016498A/ko active Pending
- 2020-05-28 MA MA056021A patent/MA56021A/fr unknown
- 2020-05-28 JP JP2021570931A patent/JP7641917B2/ja active Active
- 2020-05-28 JP JP2021570930A patent/JP7644029B2/ja active Active
- 2020-05-28 CN CN202080040266.2A patent/CN114269432B/zh active Active
- 2020-05-28 EP EP20728766.5A patent/EP3976180A1/fr active Pending
- 2020-05-28 MX MX2021014115A patent/MX2021014115A/es unknown
- 2020-05-28 US US17/615,017 patent/US12466820B2/en active Active
- 2020-05-28 EP EP20728765.7A patent/EP3976179A1/fr active Pending
- 2020-05-28 US US17/615,056 patent/US20230092892A1/en active Pending
- 2020-05-28 MA MA056022A patent/MA56022A/fr unknown
- 2020-05-28 PE PE2021001962A patent/PE20220934A1/es unknown
- 2020-05-28 KR KR1020217043074A patent/KR20220016499A/ko active Pending
- 2020-05-28 WO PCT/EP2020/064913 patent/WO2020239951A1/fr not_active Ceased
- 2020-05-28 WO PCT/EP2020/064914 patent/WO2020239952A1/fr not_active Ceased
- 2020-05-28 GE GEAP202515818A patent/GEAP202515818A/en unknown
- 2020-05-28 CN CN202410508911.9A patent/CN118239931A/zh active Pending
- 2020-05-28 CN CN202080039837.0A patent/CN113891745B/zh active Active
- 2020-05-28 MX MX2021014113A patent/MX2021014113A/es unknown
- 2020-05-28 BR BR112021021738A patent/BR112021021738A2/pt unknown
- 2020-05-28 CA CA3139019A patent/CA3139019A1/fr active Pending
- 2020-05-28 AU AU2020285336A patent/AU2020285336A1/en active Pending
- 2020-05-28 SG SG11202112187YA patent/SG11202112187YA/en unknown
- 2020-05-28 AU AU2020281923A patent/AU2020281923A1/en active Pending
- 2020-05-28 PH PH1/2021/552881A patent/PH12021552881A1/en unknown
- 2020-05-28 BR BR112021022099A patent/BR112021022099A2/pt unknown
2021
- 2021-10-26 ZA ZA2021/08273A patent/ZA202108273B/en unknown
- 2021-11-22 SA SA521430920A patent/SA521430920B1/ar unknown
- 2021-11-25 IL IL288405A patent/IL288405A/en unknown
- 2021-11-29 CL CL2021003165A patent/CL2021003165A1/es unknown
- 2021-12-14 CO CONC2021/0017031A patent/CO2021017031A2/es unknown
2025
- 2025-02-27 JP JP2025029719A patent/JP2025098014A/ja active Pending

Also Published As

Publication number	Publication date
AU2020285336A1 (en)	2022-01-06
US12466820B2 (en)	2025-11-11
MX2021014113A (es)	2021-12-10
CN114269432A (zh)	2022-04-01
GEP20257823B (en)	2025-11-10
KR20220016499A (ko)	2022-02-09
EP3976180A1 (fr)	2022-04-06
PH12021552881A1 (en)	2022-07-25
CA3139019A1 (fr)	2020-12-03
US20230092892A1 (en)	2023-03-23
BR112021022099A2 (pt)	2021-12-28
PE20220934A1 (es)	2022-05-31
CN114269432B (zh)	2024-05-07
BR112021021738A2 (pt)	2021-12-28
JP7644029B2 (ja)	2025-03-11
US20220227749A1 (en)	2022-07-21
JP2025098014A (ja)	2025-07-01
JP2022534751A (ja)	2022-08-03
WO2020239951A1 (fr)	2020-12-03
JP2022534303A (ja)	2022-07-28
CN118239931A (zh)	2024-06-25
CN113891745A (zh)	2022-01-04
SG11202112187YA (en)	2021-12-30
NZ782235A (en)	2025-03-28
CL2021003165A1 (es)	2022-09-23
MX2021014115A (es)	2021-12-10
IL288405A (en)	2022-01-01
JP7641917B2 (ja)	2025-03-07
CO2021017031A2 (es)	2022-01-17
CN113891745B (zh)	2024-05-07
AU2020281923A1 (en)	2022-01-06
EP3976179A1 (fr)	2022-04-06
ZA202108273B (en)	2023-07-26
MA56021A (fr)	2022-04-06
KR20220016498A (ko)	2022-02-09
WO2020239952A1 (fr)	2020-12-03
SA521430920B1 (ar)	2025-05-21
CA3139018A1 (fr)	2020-12-03
GEAP202515818A (en)	2025-07-10

Publication	Publication Date	Title
MA56022A (fr)	2022-04-06	Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3
MA51616A (fr)	2020-11-25	Inhibiteurs d'adn-pk
MA51619A (fr)	2021-04-14	Inhibiteurs de la protéine kinase dépendante de l'adn
ME03404B (fr)	2020-01-20	Dérivés d'amides polycycliques comme inhibiteurs de la cdk9
MA71308A (fr)	2025-04-30	Inhibiteurs de kars dépendant d'akr1c3 tricycliques
EP3999517A4 (fr)	2023-07-12	Inhibiteurs de cd73
EP4039536A4 (fr)	2022-11-23	Rail de coulissement d'accueil
MA52004A (fr)	2021-01-20	Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
EP3919491A4 (fr)	2022-10-19	Inhibiteur d'akt
MA54521A (fr)	2022-03-30	Dérivés d'oxopyridine substitués
MA53643A (fr)	2021-12-29	Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6
EP3820980A4 (fr)	2022-07-13	Compositions d'esterquats
EP4069688C0 (fr)	2025-10-01	Composés aminés hétéroaromatiques bicycliques fusionnés à action pesticide
EP3774739A4 (fr)	2021-08-25	Dérivés d'urée cyclique fusionnés utilisés comme antagonistes de crhr2
EP3992176A4 (fr)	2022-08-24	Antagoniste d'ep2
MA53648A (fr)	2021-07-28	Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase
EP3917926C0 (fr)	2025-10-01	Dérivés d'imidazoquinoline amine, composition pharmaceutique, utilisation de ceux-ci
EP3939588A4 (fr)	2023-01-11	Utilisations d'inhibiteurs de la phosphodiestérase
EP3844166C0 (fr)	2023-07-12	Macrocycles substitués utiles en tant qu'inhibiteurs de kinase
MA53164A (fr)	2021-05-26	Dérivés de tyrosine amide utilisés en tant qu'inhibiteurs de la rho-kinase
MA51283A (fr)	2021-05-26	Dérivés de tyrosine en tant qu'inhibiteurs de kinase rho
EP3913022A4 (fr)	2022-10-19	Agent de revêtement d'ancrage
EP3855516A4 (fr)	2022-07-06	Composition d'étanchéité
MA51284A (fr)	2021-05-26	Dérivés d'oxadiazole en tant qu'inhibiteurs de kinase rho
MA52891A (fr)	2021-04-28	Dérivés aza-indoliques utilisés comme inhibiteurs de rho-kinase